Company Overview
About Beckley Psytech
Beckley Psytech is a UK-based clinical-stage biotechnology company developing psychedelic-derived medicines for neuropsychiatric disorders, with a primary focus on treatment-resistant depression (TRD). Its lead asset, BPL-003, is an intranasal formulation of 5-MeO-DMT (mebufotenin benzoate) designed to deliver a controlled, short-duration psychedelic experience under medical supervision. In July 2025, Beckley Psytech and its partner atai Life Sciences reported positive topline results from a Phase 2b trial of BPL-003, with a single 8mg dose achieving a 12.1-point reduction on standardized depression scales at day 29 — a clinically meaningful outcome.
Business Model & Competitive Advantage
Following these results, the U.S. FDA granted Breakthrough Therapy Designation to BPL-003 in October 2025, recognizing its potential to substantially improve over existing therapies for TRD. The company merged with atai Life Sciences to form AtaiBeckley Inc., which plans to initiate Phase 3 trials in Q2 2026 pending FDA alignment. Financial resources are projected to support operations into 2029. Beyond BPL-003, Beckley''s pipeline includes VLS-01 (a DMT buccal film for TRD, Phase 2 data expected H2 2026) and EMP-01 (an oral R-MDMA compound for social anxiety disorder).
Competitive Landscape 2025–2026
Beckley Psytech''s scientific heritage traces to the Beckley Foundation, a leading psychedelic research organization, giving the company deep roots in psychedelic pharmacology and clinical research. Its regulatory and clinical progress positions Beckley among the most advanced psychedelic medicine programs globally, alongside COMPASS Pathways. The company''s shorter-duration 5-MeO-DMT approach aims to improve clinical feasibility compared to longer psilocybin sessions.
Key Differentiators
Emerging Innovator
Beckley Psytech is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Karius
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
Compare Beckley Psytech with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Beckley Psytech? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Beckley Psytech Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Beckley Psytech vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →